Latest news with #SureView™
Associated Press
03-06-2025
- Business
- Associated Press
Austria's Tyrolpath Leads Europe with First Clinical Adoption of Techcyte's SureView™
Tyrolpath launches Europe's first SureView™ installation, combining AI, imaging, and automation for high-volume cervical cytology. 'Dr. Obrist and his team are pioneers in adopting new technologies to advance patient care, and we are proud to support their vision with our AI-driven solutions.'— Ben Cahoon, Chief Executive Officer of Techcyte OREM, UT, UNITED STATES, June 3, 2025 / / -- Techcyte, leader in AI-powered digital pathology, announced today the first European clinical implementation of its Techcyte SureView™ cervical cytology solution at Tyrolpath, one of the largest private pathology laboratories in Austria. In partnership with BD, Techcyte's exclusive global distributor for Techcyte SureView™, this milestone marks a significant advancement in the digital transformation of cervical cancer screening in Europe. Tyrolpath, located in Zams, Austria, processes hundreds of thousands of Pap smears annually. To manage this volume, and lay the foundation for future diagnostic applications, Tyrolpath acquired the Pramana Spectral HT-4 scanner — the only open, multipurpose whole slide imaging system to offer smart, inline, volumetric scanning, providing high-throughput capacity, redundancy, and the flexibility to support multiple indications. The lab has integrated Techcyte's SureView™ platform alongside BD's SurePath™ liquid-based cytology, creating an automated, end-to-end cervical cancer screening workflow from sample collection through digital review. 'We are thrilled to see Tyrolpath leading the way in Europe,' said Ben Cahoon, Chief Executive Officer of Techcyte. 'Dr. Obrist and his team are pioneers in adopting new technologies to advance patient care, and we are proud to support their vision with our AI-driven solutions.' Dr. Peter Obrist, owner of Tyrolpath and a key opinion leader in cytology, remarked, 'SureView™ brings a new level of confidence to cervical screening. The combination of BD SurePath™ preparation, Pramana's high-quality imaging, and Techcyte's AI analysis enables us to maintain the highest diagnostic standards while preparing for the future of digital pathology.' Sandra Knöthig, Product Manager Women'sHealth & Cancer C&EE from BD added, 'This collaboration marks an important step in the evolution of cervical cancer screening. Our partnership with Techcyte and Tyrolpath demonstrates how innovation can be scaled to meet the needs of high-volume laboratories while laying the groundwork for broader diagnostic applications.' This implementation reflects a growing interest across Europe in modernizing cytology workflows through integrated, digital solutions. As partners explore the broader potential of AI and automation in laboratory diagnostics, this collaboration serves as an example of how technology and expertise can come together to support the evolving needs of clinical practice. Troy Bankhead Techcyte + +1 435 210-6200 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Malaysian Reserve
28-05-2025
- Health
- Malaysian Reserve
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. 'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.' For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information.
Yahoo
27-05-2025
- Health
- Yahoo
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. "We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!" Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. "Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact." For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System - Rivera Rolon - 2025 - Cancer Cytopathology - Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information. View original content to download multimedia: SOURCE CorePlus Servicios Clinicos y Patologicos, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
